558482-75-0

Basic information

• Product Name: L-Serine, O-(4-bromophenyl)-N-(triphenylmethyl)-, methyl ester
• CAS NO: 558482-75-0
• Molecular Formula: C29H26BrNO3
• Molecular Weight: 516.434
• Mol File: 558482-75-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: L-Serine, O-(4-bromophenyl)-N-(triphenylmethyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Serine, O-(4-bromophenyl)-N-(triphenylmethyl)-, methyl ester(558482-75-0)
• EPA Substance Registry System: L-Serine, O-(4-bromophenyl)-N-(triphenylmethyl)-, methyl ester(558482-75-0)

Safety Data

• Hazardous Substances Data: 558482-75-0(Hazardous Substances Data)

Upstream product

• 76-83-5 trityl chloride 
• 106-41-2 4-bromo-phenol 
• 13515-76-9 methyl N-trityl-L-serinate 

Downstream Products

• 441348-00-1 methyl O-(3'-amino-1,1'-biphenyl-4-yl)-N-triphenylmethyl-L-serinate 
• 942064-69-9 2-amino-3-(4-bromophenoxy)-propionic acid methyl ester 
• 441348-02-3 (S)-3-[3'-(3-Propyl-ureido)-biphenyl-4-yloxy]-2-(trityl-amino)-propionic acid methyl ester 
• 441348-16-9 Methyl N-(mesitylsulfonyl)-O-(3'-{[(propylamino)carbonyl]amino}-1,1'-biphenyl-4-yl)-L-serinate 

Relevant articles and documents

Methodology for Synthesis of Enantiopure 3,5-Disubstituted Pyrrol-2-ones

A new synthetic route towards chiral 3,5-disubstituted pyrrol-2-ones by starting from amino acids has been developed. The sequence features the conversion of amino acids into their corresponding alkynoic acid derivative followed by a Pd-catalyzed hydrosta

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

Biphenyls as potent vitronectin receptor antagonists. Part 2: Biphenylalanine ureas

Vitronectin receptor (αVβ3) antagonism has been implicated in a variety of disease states, like restenosis, osteoporosis and cancer. In this work, we present the development of a novel class of biphenyl vitronectin receptor antagonists. Identified from a focused combinatorial library based on para-bromo phenylalanine, these compounds show nanomolar affinity to the vitronectin receptor and display unprecedented SAR. Their binding mode can be rationalized by computational docking studies using the X-ray structure of αVβ3.